STOCKHOLM - April 24, 2026 - Inify Laboratories, a unique laboratory service
that provides diagnostics in pathology, has entered into an agreement with the
Swedish Region Jämtland Härjedalen. The agreement involves the delivery of
specialised prostate cancer diagnostics with the aim of shortening waiting times
for results to patients with suspected cancer.

"The collaboration means that the region's patients undergoing prostate cancer
investigation are offered diagnostics in a completely digital and traceable
workflow with the highest possible patient safety", says Meriana Findakly,
Department Manager of Laboratory Medicine in Region Jämtland Härjedalen.

In large parts of the Western world, pathology is under enormous pressure, with
an extensive workload and limited resources. One of the parts that is affected
is prostate cancer diagnostics, resulting in long and varying lead times. Like
most other regions in Sweden, Region Jämtland Härjedalen has challenges in
achieving the targets that have been developed within the framework of the
standardised patient pathway targets for prostate cancer, stipulating that the
patient should be notified within 11 days of the examination.

The goal of the collaboration is to shorten waiting times for patients while
making it easier for urologists to interpret test results and plan treatment.
Guaranteed and short response times have the potential to facilitate planning.
In addition, urologists receive a visual and standardised pathology report that
clearly shows where there is cancer or not, which in turn can reduce the risk of
misinterpretation.

 The region's prostate biopsy samples will be sent to Inify Laboratories in
Stockholm for tissue preparation and digitisation. Inify's pathologists make a
diagnosis with the support of the company's AI-based decision support tool and
the report is made available for the urologists, well in advance to meet the SVF
targets.

"We are very much looking forward to the collaboration, which will also be a
confirmation of Inify's capacity to deliver diagnostics to all parts of Sweden
and thus contribute to equal care with shortened waiting times and high
quality," says Maria Holmberg, Sales and Marketing Manager at Inify
Laboratories.

For further information, please contact CEO, Fredrik Palm,
[email protected], or visit https://www.inify.com.

###

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 the Norwegian Securities Trading
Act. This stock exchange announcement was published by Ann-Charlotte Linderoth,
Inify Laboratories AB on the time and date provided.

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)